Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
Murielle Roussel, Philippe Moreau, Benjamin Hebraud, Kamel Laribi, Arnaud Jaccard, Mamoun Dib, Borhane Slama, Véronique Dorvaux, Bruno Royer, Laurent Frenzel, Sonja Zweegman, Saskia K Klein, Annemiek Broijl, Kon-Siong Jie, Jianping Wang, Veronique Vanquickelberghe, Carla de Boer, Tobias Kampfenkel, Katharine S Gries, John FastenauPieter Sonneveld*
*Corresponding author for this work
Research output: Contribution to journal › Article › Academic › peer-review
28Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.